

32-1349: IGFBP3 Recombinant Protein

Alternative Name : Growth-hormone-dependant binding protein, IBP3, BP-53, IGFBP-3.

Description

Source : Escherichia Coli. IGFBP3 Human Recombinant produced in E.Coli is a homodimeric, non-glycosylated, polypeptide chain containing 2x264 amino acids and having a molecular mass of 28806 Dalton. IGFBP-3 is purified by proprietary chromatographic techniques. IGFBP3 is a member of the insulin-like growth factor binding protein (IGFBP) family and encodes a protein with an IGFBP domain and a thyroglobulin type-I domain. The protein forms a ternary complex with insulin-like growth factor acid-labile subunit (IGFALS) and either insulin-like growth factor (IGF) I or II. In this form, it circulates in the plasma, prolonging the half-life of IGFs and altering their interaction with cell surface receptors. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.

Product Info

Amount :	25 µg
Purification :	Greater than 97.0% as determined by:(a) Analysis by RP-HPLC.(b) Analysis by SDS-PAGE.
Content :	Lyophilized from a 0.2µm filtered concentrated (0.5mg/ml) solution in PBS, pH 7.4.
Storage condition :	Lyophilized IBP3 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution IGF-BP 3 should be stored at 4°C between 2-7 days and for future use below -18°C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please prevent freeze-thaw cycles.
Amino Acid :	GASSGGLGPV VRCEPCDARA LAQCAPPVAV CAELVREPGC GCCLTCALSE GQPCGIYTER CGSGLRCQPS PDEARPLQAL LDGRGLCVNA SAVSRLRAYL LPAPPAPGNA SESEEDRSAG EVESPSVSST HRVSDPKFHP LHSKIIIIKK GHAKDSQRYK VDYESQSTD T QNFSSSESKRE TEYGPCRREM EDTLNHLKFL NVLSPRGVHI PNCDDKKGFYK KKQCRPSKGR KRGFCWCVDK YGQPLPGYTT KGKEDVHCYS MQSK.

Application Note

It is recommended to reconstitute the lyophilized Insulin-Like Growth Factor Binding Protein-3 in sterile 20mM AcOH (acetic Acid) not less than 100µg/ml, which can then be further diluted to other aqueous solutions. The ED50, calculated by its ability to inhibit IGF-II induced proliferation of MCF-7 is < 0.2 µg/ml in the presence of 15 ng/ml of Human IGF-II, corresponding to a specific activity of 5,000,000units/mg.

